Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis | MicrobiomeTrials← Back to trialsNCT07376512
Predicting Response to Anti-PD-1/PD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis
RecruitingOBSERVATIONAL
Trial Details
Start: 2026-11-01Est. Completion: 2030-11-01
Enrollment target: 378 participants Locations- CHU Besançon - Service Dermatologie, Besançon, France
- CHU Besançon - Service Pneumologie Oncologie Thoracique, Besançon, France
- Centre Georges-François Leclerc, Dijon, France
- CHU Dijon - Service Oncologie Médicale, Dijon, France
- Centre Leon Berard - Service Oncologie Médicale, Lyon, France
ContactAnne-Laure ALR REROLE, Project manager
Other microbiome trials you might be interested in
Non-small Cell Lung CancerNSCLC
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed …
Little Rock, United StatesEst. completion Jan 12, 2029
Lung Non-Small Cell CarcinomaLung Non-Small Cell Squamous CarcinomaLung Non-Squamous Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of …
Anchorage, United StatesEst. completion Jan 31, 2030
Carcinoma, Non-Small-Cell Lung
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet…
Birmingham, United StatesEst. completion Sep 7, 2029